Mycophenolate as induction therapy in lupus nephritis with renal function impairment

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Lupus nephritis (LN) treatment often involves induction therapy.
• Mycophenolate (MF) is a known effective treatment for LN in patients with normal renal function.
• The efficacy of MF in patients with impaired renal function in LN is not well-established.

Purpose of the Study:

• To evaluate the response to Mycophenolate (MF) in lupus nephritis (LN) patients.
• To determine the association between MF response and baseline renal function in LN patients.

Main Methods:

• A retrospective study of 90 lupus nephritis (LN) patients receiving Mycophenolate (MF) induction therapy.
• Patients were divided into two groups based on baseline estimated glomerular filtration rate (eGFR): ≥60 ml/min/1.73 m² (Group 1) and <60 ml/min/1.73 m² (Group 2).
• Primary outcome was the percentage of patients achieving any response; secondary outcomes included complete response (CR), partial response (PR), relapses, and side effects.

Main Results:

• No significant differences in baseline parameters or exposure to prednisone and MF between groups.
• At 6 months, response rates were 69.2% (Group 1) and 43.8% (Group 2); at 12 months, rates were 81.3% (Group 1) and 73.7% (Group 2).
• Complete response (CR) was more frequent in Group 1, while partial response (PR) was similar in both groups. Relapses and side effects were infrequent.

Conclusions:

• Mycophenolate (MF) is an effective and safe induction therapy for lupus nephritis (LN).
• Patients with baseline renal impairment can achieve a response to MF treatment for LN.
• MF demonstrates efficacy across a spectrum of renal function in LN patients.